81 related articles for article (PubMed ID: 16529931)
1. SAR studies: designing potent and selective LXR agonists.
Szewczyk JW; Huang S; Chin J; Tian J; Mitnaul L; Rosa RL; Peterson L; Sparrow CP; Adams AD
Bioorg Med Chem Lett; 2006 Jun; 16(11):3055-60. PubMed ID: 16529931
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and SAR of potent LXR agonists containing an indole pharmacophore.
Washburn DG; Hoang TH; Campobasso N; Smallwood A; Parks DJ; Webb CL; Frank KA; Nord M; Duraiswami C; Evans C; Jaye M; Thompson SK
Bioorg Med Chem Lett; 2009 Feb; 19(4):1097-100. PubMed ID: 19167885
[TBL] [Abstract][Full Text] [Related]
3. 2-Aryl-N-acyl indole derivatives as liver X receptor (LXR) agonists.
Kher S; Lake K; Sircar I; Pannala M; Bakir F; Zapf J; Xu K; Zhang SH; Liu J; Morera L; Sakurai N; Jack R; Cheng JF
Bioorg Med Chem Lett; 2007 Aug; 17(16):4442-6. PubMed ID: 17587573
[TBL] [Abstract][Full Text] [Related]
4. Design, structure activity relationships and X-Ray co-crystallography of non-steroidal LXR agonists.
Bennett DJ; Carswell EL; Cooke AJ; Edwards AS; Nimz O
Curr Med Chem; 2008; 15(2):195-209. PubMed ID: 18220775
[TBL] [Abstract][Full Text] [Related]
5. Novel peroxisome proliferator-activated receptor alpha agonists lower low-density lipoprotein and triglycerides, raise high-density lipoprotein, and synergistically increase cholesterol excretion with a liver X receptor agonist.
Mukherjee R; Locke KT; Miao B; Meyers D; Monshizadegan H; Zhang R; Search D; Grimm D; Flynn M; O'Malley KM; Zhang L; Li J; Shi Y; Kennedy LJ; Blanar M; Cheng PT; Tino J; Srivastava RA
J Pharmacol Exp Ther; 2008 Dec; 327(3):716-26. PubMed ID: 18799592
[TBL] [Abstract][Full Text] [Related]
6. Discovery of substituted maleimides as liver X receptor agonists and determination of a ligand-bound crystal structure.
Jaye MC; Krawiec JA; Campobasso N; Smallwood A; Qiu C; Lu Q; Kerrigan JJ; De Los Frailes Alvaro M; Laffitte B; Liu WS; Marino JP; Meyer CR; Nichols JA; Parks DJ; Perez P; Sarov-Blat L; Seepersaud SD; Steplewski KM; Thompson SK; Wang P; Watson MA; Webb CL; Haigh D; Caravella JA; Macphee CH; Willson TM; Collins JL
J Med Chem; 2005 Aug; 48(17):5419-22. PubMed ID: 16107141
[TBL] [Abstract][Full Text] [Related]
7. Discovery and SAR of cinnolines/quinolines as liver X receptor (LXR) agonists with binding selectivity for LXRbeta.
Hu B; Unwalla R; Collini M; Quinet E; Feingold I; Goos-Nilsson A; Wihelmsson A; Nambi P; Wrobel J
Bioorg Med Chem; 2009 May; 17(10):3519-27. PubMed ID: 19394832
[TBL] [Abstract][Full Text] [Related]
8. RXR-LXR heterodimer modulators for the potential treatment of dyslipidemia.
Lagu B; Pio B; Lebedev R; Yang M; Pelton PD
Bioorg Med Chem Lett; 2007 Jun; 17(12):3497-503. PubMed ID: 17485209
[TBL] [Abstract][Full Text] [Related]
9. Combating atherosclerosis with LXR alpha and PPAR alpha agonists: is rational multitargeted polypharmacy the future of therapeutics in complex diseases?
Kino T; Chrousos GP
Mol Interv; 2004 Oct; 4(5):254-7. PubMed ID: 15471908
[No Abstract] [Full Text] [Related]
10. [Synthesis of (24S)-hydroxy- and (24S)-24,25-epoxycholesterol analogues, potential agonists of nuclear LXR receptors].
Khripach VA; Zhabinskiĭ VN; Antonchik AV; Antonchik AP
Bioorg Khim; 2006; 32(6):651-9. PubMed ID: 17180916
[TBL] [Abstract][Full Text] [Related]
11. Synthetic LXR agonists increase LDL in CETP species.
Groot PH; Pearce NJ; Yates JW; Stocker C; Sauermelch C; Doe CP; Willette RN; Olzinski A; Peters T; d'Epagnier D; Morasco KO; Krawiec JA; Webb CL; Aravindhan K; Jucker B; Burgert M; Ma C; Marino JP; Collins JL; Macphee CH; Thompson SK; Jaye M
J Lipid Res; 2005 Oct; 46(10):2182-91. PubMed ID: 16024916
[TBL] [Abstract][Full Text] [Related]
12. LXR agonists for the treatment of atherosclerosis.
Jaye M
Curr Opin Investig Drugs; 2003 Sep; 4(9):1053-8. PubMed ID: 14582448
[TBL] [Abstract][Full Text] [Related]
13. HDL-C as a new paradigm in atherosclerotic diseases.
Shilpha S; Bairy KL
Indian J Physiol Pharmacol; 2008; 52(4):319-26. PubMed ID: 19585750
[No Abstract] [Full Text] [Related]
14. Steroidal and triterpenoidal fungal metabolites as ligands of liver X receptors.
Ondeyka JG; Jayasuriya H; Herath KB; Guan Z; Schulman M; Collado J; Dombrowski AW; Kwon SS; McCallum C; Sharma N; MacNaul K; Hayes N; Menke JG; Singh SB
J Antibiot (Tokyo); 2005 Sep; 58(9):559-65. PubMed ID: 16320760
[TBL] [Abstract][Full Text] [Related]
15. Carboxylic acid based quinolines as liver X receptor modulators that have LXRbeta receptor binding selectivity.
Hu B; Quinet E; Unwalla R; Collini M; Jetter J; Dooley R; Andraka D; Nogle L; Savio D; Halpern A; Goos-Nilsson A; Wilhelmsson A; Nambi P; Wrobel J
Bioorg Med Chem Lett; 2008 Jan; 18(1):54-9. PubMed ID: 18023179
[TBL] [Abstract][Full Text] [Related]
16. Indazole-based liver X receptor (LXR) modulators with maintained atherosclerotic lesion reduction activity but diminished stimulation of hepatic triglyceride synthesis.
Wrobel J; Steffan R; Bowen SM; Magolda R; Matelan E; Unwalla R; Basso M; Clerin V; Gardell SJ; Nambi P; Quinet E; Reminick JI; Vlasuk GP; Wang S; Feingold I; Huselton C; Bonn T; Farnegardh M; Hansson T; Nilsson AG; Wilhelmsson A; Zamaratski E; Evans MJ
J Med Chem; 2008 Nov; 51(22):7161-8. PubMed ID: 18973288
[TBL] [Abstract][Full Text] [Related]
17. Liver X receptor agonists with selectivity for LXRbeta; N-aryl-3,3,3-trifluoro-2-hydroxy-2-methylpropionamides.
Swahn BM; Macsari I; Viklund J; Ohberg L; Sjödin J; Neelissen J; Lindquist J
Bioorg Med Chem Lett; 2009 Apr; 19(7):2009-12. PubMed ID: 19264481
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and structure-activity relationship of podocarpic acid amides as liver X receptor agonists for potential treatment of atherosclerosis.
Liu W; Chen S; Dropinski J; Colwell L; Robins M; Szymonifka M; Hayes N; Sharma N; MacNaul K; Hernandez M; Burton C; Sparrow CP; Menke JG; Singh SB
Bioorg Med Chem Lett; 2005 Oct; 15(20):4574-8. PubMed ID: 16125384
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic opportunities for liver X receptor modulators.
Collins JL
Curr Opin Drug Discov Devel; 2004 Sep; 7(5):692-702. PubMed ID: 15503871
[TBL] [Abstract][Full Text] [Related]
20. Further modification on phenyl acetic acid based quinolines as liver X receptor modulators.
Hu B; Jetter J; Kaufman D; Singhaus R; Bernotas R; Unwalla R; Quinet E; Savio D; Halpern A; Basso M; Keith J; Clerin V; Chen L; Liu QY; Feingold I; Huselton C; Azam F; Goos-Nilsson A; Wilhelmsson A; Nambi P; Wrobel J
Bioorg Med Chem; 2007 May; 15(10):3321-33. PubMed ID: 17391964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
